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Abstract 
Background: Local recurrence in oral squamous cell carcinoma (OSCC) despite clear 
surgical margins may indicate the presence of residual, sub-microscopic disease.  
Molecular assessment of surgical margins may provide a greater prognostic sensitivity 
compared to histopathology. We aim to determine whether promoter methylation in 
deep and mucosal resection margins can predict recurrence in OSCC. 
Methods: 48 consecutive OSCC cases were recruited and a 5mm3 tumour sample plus 5 
deep and 5 mucosal margin samples snap frozen.  Clinical, pathological, adjuvant 
therapy and outcome data were recorded.  Tumours were informative if >5% promoter 
methylation was found for ≥1 of 4 genes using qMSP. Margins were declared 
molecularly positive if >1% promoter methylation was found in any margin. 
Results: 30/48 (63%) cases were methylation-informative. Mucosal margin samples 
were largely positive for methylation (26/30; 87%) indicating the presence of field 
cancerisation. Methylation at ≥1 gene promoters in ≥1 deep margin correlated with the 
presence of close/involved mucosal margins (P=0.027) and increased pT status 
(P=0.027) but not the status of deep margins, recurrence or survival. 
Conclusions: The current gene panel did not add prognostic information to 
histopathological reporting of resection margins. Future efforts should concentrate on 
improving gene selection, informativity and assay performance in the patient group 
with intermediate indications for adjuvant therapy. 
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Introduction 
 
The principal aim of surgical ablation for malignancy is to achieve clear resection 
margins. These are routinely defined by histopathology , where an additional 5mm of 
‘normal’ tissue beyond the tumour should be identified in three dimensions [1]. This 
requirement is based on the assumption that histopathologically invisible cancer cells 
exist within this margin and might explain the common finding of local recurrence 
despite histopathologically defined clear margins [2].  In head and neck cancer (HNSCC), 
the temptation to increase excision margins to minimise local recurrence must be 
tempered against the concern of unjustified and irreversible loss of function.  For this 
reason, the novel staging methodologies, such as molecular staging, have been explored 
to a greater extent in head and neck surgery than other surgical disciplines [3] with a 
view to providing a greater sensitivity for the detection of local recurrence.   
 
The technical and theoretical hurdles to be overcome are, however, substantial.  Firstly, 
the assay should be robust and clinically applicable. Ideally, the molecular aberration 
should be observed with high specificity, i.e. in the tumour but not in normal tissues, 
and informativity, i.e. in all or a high percentage of cases. Additionally, an assay needs to 
be developed that identifies this aberration with high sensitivity, and the technical 
platform should be reliable, reproducible, inexpensive and applicable in routine clinical 
practice. Secondly, it must be clear that an appropriate and effective intervention is 
available for cases with molecularly involved but histologically clear margins.  It is 
known that involved and close margins are associated with other markers of biological 
aggression [4] such as T stage, N stage and extra-capsular spread (ECS) in regional 
lymph nodes [5, 6], and it is a matter for debate if increasing the surgical margin could 
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prevent tumour recurrence in such cases.  Thirdly, the extent to which the entire 
surgical margin can be assessed by any technique (conventional or molecular) requires 
assessment. It follows that the reliability of any decision made on the basis of margins 
only, rather than an overall decision made on multiple markers of recurrence, might be 
questionable. 
  
Molecular margin analysis has been investigated using a number of techniques. Given 
their high frequency in HNSCC, p53 mutations have traditionally been used [7, 8] but 
there are many sites where mutation has been shown to occur in this large gene with 
multiple exons.  As such, the potentially attractive, sensitive PCR assay for any 
individual mutation offers very poor informativity, and the complex plaque phage 
functional assays for p53 are expensive and difficult to implement clinically.  The 
common sites for chromosomal allelic loss in HNSCC have been explored as alternative 
molecular biomarkers of margin involvement [9, 10], but here the potential for highly 
sensitive assays is limiting. In contrast promoter hypermethylation is common [11], 
exists in a homogenous form [12] that can be detected by a single assay when present, 
and can be detected with high sensitivity [13, 14].  Previous analyses of promoter 
hypermethylation in HSNCC [15-19], as well as resection of liver [20] and lung [21] 
malignancies, are characterised by small cohort size, analysis of a limited number of 
margin samples, and a lack of distinction between mucosal and deep margins. 
Importantly there have been a variety of methylation detection assays used with little 
consensus or justification for the cut-off at which a margin might be declared reliably 
positive.   
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The aims of this study are to evaluate DNA hypermethylation in the analysis of surgical 
margins using a consecutive cohort of oral squamous cell carcinoma (OSCC) patients 
treated by primary surgery.  We will focus on quantitative methylation analysis using 
real time quantitative methylation-specific PCR (qMSP) assays in DNA derived from 
multiple fresh-frozen margin samples from each case. The overall informativity of a 
panel of gene promoter methylation markers, as well as their individual contribution 
will be defined. The ability of methylation status of deep margins, and separately, 
mucosal margins, in predicting recurrence will be defined and compared with the 
histopathologically reported margin status and other clinicopathological features.  
 
Methods 
Clinical 
53 consecutive OSCC patients were selected for inclusion in this study over the period 
1st April 2007 – 30th April 2008, and all gave informed consent under a specific 
institutional ethical approval (REC 07/Q1505/15).  No power calculation was 
undertaken as this was designed as a pilot study.  Inclusion criteria were histologically 
confirmed stage T2-T4 OSCC with a treatment decision for primary surgery.  FiveT1 
tumours presenting over this time period were excluded from the study in order to 
enrich for cases likely to show either involved margins or local recurrence, leaving 48 
tumours for analysis. Following surgical resection, thorough irrigation of the tumour 
bed was carried out with 1000ml of 0.9% NaCl applied though a pressurised giving set. 
Subsequently, five mucosal (peripheral) and five deep margin samples, 5mm3, were 
randomly selected and surgically excised prior to reconstruction.  Intra-operative 
frozen sections were not taken, as is the norm for UK practice. These samples were 
placed in 10 separately pre-labeled containers and immediately frozen and stored at -
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80C until DNA preparation. An additional frozen sample was taken from the primary 
tumour and stored similarly.  Detailed histopathological analysis was recorded for each 
surgical resection according to standardized protocols, together with details of adjuvant 
therapy, and the clinical outcome for each patient was recorded for a minimum of 24 
months. 
 
Laboratory 
DNA was extracted from 2mm3 of each tissue sample using a DNeasy tissue kit (Qiagen 
Ltd, UK). DNA concentration was measured by spectrophotometry and subsequently 
adjusted to 40ng/ml. Bisulphite treatment of 1µg of each sample was undertaken using 
the EZ DNA Methylation Kit (Zymo Research Corporation, Orange, CA, USA) and the 
converted DNA eluted in 30µl of 0.1 TE buffer. Human genomic DNA (4µg) was 
artificially methylated as a positive control using SssI (CpG) Methylase (New England 
Biolabs, UK). 
 
qMSP assays were used to determine DNA methylation in the promoters of p16INK4A 
(CDKN2A), cytoglobin (CYGB), E-cadherin (CDH1) and TMEFF2. The incidence of 
promoter methylation at these genes in a similar OSCC cohort had been previously 
shown to exceed 25% [12, 22, Risk et al, unpublished data]. qMSP assays were designed 
using Primer Express 3.0 software (Applied Biosystems, Foster City, CA, USA) (primer 
and probe sequences and PCR conditions used available on request). A total reaction 
volume of 25µl contained Taqman Universal Master Mix II (Applied Biosystems), 500nM 
of each primer, 250nM of probe and 100ng of bisulphite-treated DNA.  A separate assay 
utilising a methylation-independent primer/probe set specific for the ß-actin gene 
(ACTB) was used to normalise for the DNA input in each sample. Real-time PCR 
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reactions were performed on an Applied Biosystems 7500 FAST system. Dilutions (5%, 
1%, 0.5%, 0.1% and 0%) of in vitro methylated (SssI) human lymphocyte DNA made in 
untreated lymphocyte DNA were used as a reference. ΔΔCT values were generated for 
each target after normalisation by ACTB values. The RQ values were subsequently 
calculated (2-ΔΔCT) referenced to the artificially methylated samples for statistical 
analysis. All analysed data were the mean of duplicate reactions. 
 
For tumour specimens, a threshold of 5% methylation was used to define a sample that 
was methylated at that particular gene promoter, and hence the case was deemed to be 
informative for that marker. This threshold was based on our previous methylation data 
using a variety of techniques and HNSCC tumour types [12, 23] and has been used in 
other similar studies [17].  Both 1% and 0.1% methylation were considered as possible 
thresholds for a positive margin, irrespective of whether deep or mucosal in origin.  A 
threshold of 1% was chosen for the analyses presented in this paper as this was the 
lowest value for which reproducible assignment of methylation positivity could be 
obtained in the present series of samples containing variable numbers of tumour cells 
diluted with ‘normal’ cells. 
 
Statistical analysis 
The Statistical Package for the Social Sciences (SPSS, v 18, Chicago) was used to 
undertake statistical analysis, including Chi-square test for categorical data and Kaplan-
Meier survival analysis. 
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Results 
Clinical characteristics of the cohort 
Of the 48 OSCC patients used in this study, 5 were lost to follow up and 6 had 
incomplete pathological information.  The cohort was compared clinically and 
demographically with a larger HNSCC population (n=489) from the same geographic 
location in order to confirm that they were representative of this larger cohort [5].  The 
only significant differences between the two populations were an increased incidence of 
higher pathological stage (p=0.022), the use of post-operative, adjuvant treatment 
(p=0.008) and presence of neck dissection (p=0015) in the cohort for the current study.  
These are a direct consequence of excluding T1 tumors in this cohort.   
 
Promoter methylation  
Thirty of 48 tumours (63%) demonstrated ≥5% promoter methylation at ≥1 gene.  
Thirteen tumours (26%) were methylated at TMEFF2, 11 (22%) at p16, 9 (18%) at 
CDH1 and 8 (16%) at CYGB.  The ‘promoter positive’ cohort had a younger profile than 
the ‘promoter negative’ cohort (p=0.048), while the ‘promoter negative’ cohort 
contained more large (p=0.018), well differentiated (p=0.043) tumours than the 
‘promoter positive’ cohort (Table 1).  No other statistically significant differences in 
clinical characteristics or demographic data were observed between these two groups, 
although the ‘promoter positive’ cohort showed a trend towards improved 2 year 
survival (3/26 [12%] vs 5/17 [29%]DOD; Table 1). 
 
At least one mucosal margin from 26 of the 30 informative tumours (87%) showed 
promoter methylation at ≥1 gene, while in 19 /30 (63%) at least one deep margin 
showed methylation at ≥1 gene (Supplementary table).  As gene promoter methylation 
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at mucosal margins did not appear to be discriminatory, this data was not included for 
further analysis.   
 
CDH1 promoter methylation was observed in ≥1 mucosal margin in all the positive 
tumours (9/9) and in ≥1deep margin from 8/9 positive tumours and was thus deemed 
to be not discriminatory and removed from further analyses.   
Thus, 26 tumours remained for correlation of promoter methylation at 3 genes in deep 
margin samples with clinicopathological data. 
 
Correlation of margin methylation with clinicopathological features  
Methylation at ≥1 out of 3 gene promoters in ≥1 deep margin correlated with the 
presence of close/involved mucosal margins (P=0.027), an absence of dysplasia at the 
surgical margin (P=0.024) and with tumour stage (P=0.027), most notably an increase 
in pT4 tumours (Table 2).  There was no correlation with the histopathologically 
documented presence of deep margin involvement, pattern of invasion, nodal 
involvement, ECS, recurrence, pattern of recurrence or survival. Indeed, close or 
involved pathological margins were superior to methylation of ≥1 gene promoters at 
predicting recurrence in methylation positive tumours (5/7 recurrences were in 
patients with close/involved surgical margins vs 3/7 recurrences in patients with 
methylation positive deep surgical margins).  Interestingly, histopathological 
assessment of margins was not such a good prognostic indicator for methylation 
negative tumours, where only 3/9 recurrences were in patients with close/involved 
margins (not significant: Supplementary table). 
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Of the 11 tumours with p16 promoter methylation, 7 showed concordant methylation in 
≥1 deep margin tissues.  This correlated with the presence of a non-cohesive invasive 
tumour front (P=0.015) and showed some association with the presence of 
histopathologically close or involved deep margins (Table 2). Although the numbers are 
small, there was some indication that patients with p16 positive margins presented 
with recurrence earlier than those with p16 negative margins and had a shorter 
survival period after recurrence (not significant: patients 3329,3338, 3371 & 3363, 
Supplementary table). 
 
Discussion 
 
In this study, we investigated the surgical margins in OSCC for promoter methylation as 
a predictor of clinical outcome.   30/48 tumours showed promoter methylation at  ≥1  of 
4 genes, with the incidence of individual gene promoter methylation comparable to 
those previously described using similar, quantitative assays [19], .  Mucosal margin 
samples were largely positive for methylation (26/30; 87%) supporting a concept of 
field cancerisation at this anatomical site.  As only 27% of methylation positive tumours 
recurred, it seems unlikely that the gene panel investigated in this study would have 
clinical value at mucosal margins. However, only 19/30 (63%) of deep margins were 
positive for methylation so their discriminatory effect was determined for single genes 
and for combinations of genes.  
 
Using the three gene combination of p16, TMEFF2 and CYGB, promoter methylation in 
deep margins correlated with tumour stage, indicating a greater risk of residual disease 
remaining at the deep margin.  However, this did not directly correlate with 
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pathologically involved deep surgical margins or recurrence.  The lack of association 
with recurrence may have been related to the small numbers of recurrences seen in the 
methylation positive tumours (7/26, 27%) compared to the methylation negative 
tumours (9/17, 53%). This suggests either that new methylation markers need to be 
identified, or it may confirm previous observations that tumours showing methylation 
at these specific gene promoters are inherently less aggressive [19, 22]. 
 
Analysis of data for individual genes provided some insight as to why observations 
using data from all three genes was not a good prognostic indicator.   p16 promoter 
methylation at deep margins was observed to be associated with pattern of invasion 
and possibly with close deep pathological margins and early recurrence.  Three of the 
four recurrences from tumours demonstrating p16 methylation also showed p16 
promoter methylation in the deep margins. However, four additional patients with 
methylation of this gene promoter in deep margin tissue did not recur.  Conversely, 
TMEFF2 promoter methylation in deep margins showed an association with smaller 
tumour size. These data suggest a possible role of p16 downregulation in tumour 
recurrence, while TMEFF2 may be a bystander event. 
 
The advantages of the present study over many previous reports [15-19] are that we 
have obtained snap frozen tissue with detailed pathology and at least 2 year follow-up.  
Furthermore, we have used a quantitative, real time MSP methodology with a pre-
determined cutoff.  We have also investigated mucosal and deep margins separately, 
finding mucosal margins show lack of specificity with extensive methylation in 
presumed field change.  
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Limitations of the present study include lack of informativity (30/48 tumours positive 
for promoter methylation at ≥1 genes) and the choice of biomarkers. This was 
unexpected given our previously determined incidence of informativity for these genes, 
but may reflect the different methodologies employed [12, 22]. However, previous 
published reports reflect even fewer informative cases -  a cumulative total of only 70 
informative tumours have been previously published amongst five previous series using 
methylation assays in surgical margins [15-19] 
 
Given the intensive nature of sample collection and analysis of 11 samples per tumour 
involved in this study, some conclusions regarding sample selection/pooling should be 
drawn from our data before embarking on a larger series.  We have found it difficult to 
use DNA methylation biomarkers to distinguish field change or premalignant lesions 
[24] at the mucosal margin from residual tumour.  Further, it may be more appropriate 
to sample the deep margins at several sites, but to then pool the DNA to create a single 
sample for prognostic purposes.  Similarly, the selection of the panel of biomarkers used 
in the present study was unfortunate in that one marker (CDH1) was largely 
uninformative, while the sensitivity of one other marker (CYGB) appeared to be lower 
than the other two genes, as shown by the low number of positive margins associated 
with CYGB positive tumours.  The identification of further markers with suitable 
sensitivity for inclusion in a methylation biomarker panel is required and candidates 
may yet emerge with improving genome-wide array techniques.  
 
Lastly, it is worthwhile to reflect on the clinical context for which molecular margin 
analysis may be of greatest therapeutic value. In those cases defined as the intermediate 
risk group [25] where the role for adjuvant therapy remains unproven, the value of 
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molecular margin analysis might be best highlighted. This may be particularly the case 
for those resections with close margins as a sole adverse prognostic feature.  
Concentrating future efforts on improving informativity and the utility of assay 
performance in this group seems logical.  This would clarify if these, as yet unproven, 
techniques can be translated into clinical practice. 
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Table 1  Clinical and demographic characteristics of the patient cohort used in this study 
 All tumours 
(n=48)
 
me+ tumour
a 
(n=30: 63%) 
me– tumoursb 
(n=18: 38%) 
Gender: 
           Male 
           Female 
 
33 (72%) 
13 (28%) 
 
20 (71%) 
  8 (29%) 
 
13 (72%) 
  5 (28%) 
Age: 
           < 55 
          55-64 
          65-74 
          75+ 
 
13 (28%) 
21 (45%) 
8 (17%) 
5 (11%) 
 
12 (41%) 
10 (34%) 
  5 (17%) 
  2 (7%) 
 
  1 (6%) 
11 (61%) 
  3 (17%) 
  3 (17%)
* 
Tumour site: 
           Buccal 
           Lower gum 
           Tongue (ant 2/3) 
           Floor of mouth 
           Other 
 
5 (11%) 
7 (15%) 
16 (34%) 
11 (23%) 
8 (17%) 
 
2   (7%) 
5 (17%) 
9 (31%) 
6 (21%) 
7 (24%) 
 
3 (17%) 
2 (11%) 
7 (39%) 
5 (28%) 
1   (6%) 
Tumour differentiation: 
            Poor 
            Moderate 
            Well 
 
  2 (5%) 
28 (67%) 
12 (29%) 
 
  1 (4%) 
21 (81% 
  4 (15%) 
 
  1 (6%) 
  7 (44%) 
  8 (50%)
* 
Invasive front
c
: 
           Cohesive 
           Non-cohesive 
 
 
11 (24%) 
 
35 (76%) 
 
   
9 (31%) 
 
20 (69%) 
 
   
2 (12%) 
 
15 (88%) 
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Mucosal margins: 
            Clear ≥ 5mm 
            Close < 5mm 
            Involved 
 
24 (51%) 
16 (34%) 
  7 (15%) 
 
14 (48%) 
  9 (31%) 
  6 (21%) 
 
10 (56%) 
  7 (39%) 
  1 (6%) 
Deep margins: 
            Clear ≥ 5mm 
            Close < 5mm 
            Involved 
 
22 (51%) 
17 (40%) 
  4 (9%) 
 
11 (42%) 
12 (46%) 
  3 (12%) 
 
11 (65%) 
  5 (29%) 
  1 (6%) 
pT:       T1/T2 
            T3/T4 
24 (51%) 
23 (49%) 
15 (52%) 
14 (48%) 
9 (50%) 
9 (50%) 
pN:      0 
            1 
            2-3 
24 (52%) 
  6 (13%) 
16 (35%) 
18 (62%) 
  3 (10%) 
  8 (28%) 
  6 (35%) 
  3 (18%) 
  8 (47%) 
p stage: 2 
             3 
             4 
  11 (24%) 
  7 (15%)
 
28 (61%) 
   8 (28%) 
  4 (14%) 
17 (59%) 
  3 (18%) 
  3 (18%)   
11 (65%) 
Nodal status: 
          N0 
          N+ ECS – 
          N+ ECS + 
 
24 (52%) 
10 (22%) 
12 (26%) 
 
18 (62%) 
  6 (21%) 
  5 (17%) 
 
  6 (35%) 
  4 (24%) 
  7 (41%) 
Adjuvant radiotherapy 
            Yes 
            No 
 
26 (60%) 
17 (40%)
 
 
17 (65%) 
  9 (35%) 
 
9 (53%) 
8 (47%) 
Recurrence: 
            Yes 
 
16 (37%) 
 
7 (27%) 
 
9 (53%) 
18 
 
            No 27 (63%) 19 (73%) 8 (47%) 
2 yr Survival: 
            Disease free 
            DOD 
            Died (other) 
 
32 (74%) 
8 (19%) 
3 (7%) 
 
21 (81%) 
  3 (12%) 
2 (8%) 
 
11 (65%) 
5 (29%) 
1 (6%) 
 
a  me+ tumours: tumours showing ≥5% methylation at ≥ 1 gene promoter 
b  me- tumours: tumours showing <5% methylation at all gene promoters 
c invasive front classified into cohesive and non-cohesive patterns 
ECS: Extracapsular spread; DOD: Died of disease 
*  p=0.05 
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Table 2  Correlation of methylation at deep margins with clinicopathological parameters 
 Gene Promoter Methylation at: 
 p16  
and/or TMEFF2 
 and/or CYGB 
P16 alone TMEFF alone CYGB alone 
Close/involved deep 
margins 
ns 0.071 ns ns 
Close/involved 
mucosal margins 
0.027 ns ns ns 
Invasive front
a 
ns 0.015 ns ns 
Depth ns ns ns ns 
Nodes/ECS
b 
ns ns ns ns 
ECS ns ns ns ns 
Nodes ns ns ns ns 
Stage 0.074 ns ns ns 
pT   (pT2 v pT3 v pT4) 
        (pT2/3 v pT4) 
0.027 
0.035 
ns 
ns 
0.043 
ns 
ns 
ns 
Anneroth score ns ns 0.032 ns 
Recurrence ns ns ns ns 
DSS
c 
ns ns ns ns 
OS
d 
ns ns ns ns 
  
a invasive front classified into cohesive and non-cohesive 
b ECS: extracapsular spread 
 c DSS: Disease-specific survival 
d OS: Overall survival 
